OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04694300|
Recruitment Status : Recruiting
First Posted : January 5, 2021
Last Update Posted : February 16, 2021
|Condition or disease||Intervention/treatment||Phase|
|Osseointegrated Dental Implantation Pain, Acute||Drug: Naproxen Drug: Acetaminophen Drug: Tramadol||Phase 4|
Placement of dental implants is a frequently performed outpatient surgical procedure, with United States dentists currently placing implants in approximately 500,000 patients per year.This procedure has become the gold standard for replacing missing teeth due to its high level of predictability and patient acceptance, with long-term success rates greater than 95%. Thus, the number of patients opting for this procedure over dentures and fixed bridges continues to increase. In the period between 1999 and 2000 only 0.7% of the USA population had missing teeth with implants in contrast to 5.7% between 2015 and 2016 It is estimated that by 2026, if the current pace of dental implant placement continues, approximately 17% of the population will have dental implants.
Dental implant surgery involves the incision of gingival tissue to expose the underlying bone, followed by the creation of a precise bony cavity where the implant will be placed using a specialized surgical drill, and lastly the screwing of the implant into bone using a specialized handpiece Thus, it is not surprising that post-surgical pain is a common sequela following dental implant surgery. Patients often experience post-surgical pain for several days after the placement of one to three dental implants, but at a pain intensity level that is generally less than that of dental impaction surgery. This post-surgical pain is inflammatory in nature; thus, NSAIDs have demonstrated efficacy and are the preferred analgesics in this patient population. Postoperative administration of intranasal ketorolac (SPRIX®) and oral acetaminophen 325 mg plus codeine 30 mg have both demonstrated efficacy.
The soft tissue and bony trauma associated with dental implant surgery upregulates inflammatory mediators both locally and systemically. Elevated levels of interleukin (IL)-6, IL-8, and macrophage inflammatory protein (MIP)-1β have been observed in gingival crevicular fluid (GCF) from the implant site and the adjacent teeth one week after surgery. Prostaglandin E2 has been measured in the GCF of teeth surrounding implant sites employing similar methodology. Additionally, standard periodontal flap and bony recontouring surgery, which shares many similarities to dental implant surgery, induces an upregulation in immunoreactive prostaglandin E2 and leukotriene B4 levels at the surgical site. Dental implant surgery also increases cytokine levels in plasma, indicative of a systemic inflammatory response. Thus, in addition to being a model to study the efficacy and tolerability of OTC analgesics, dental implant surgery also appears to be an excellent model to study the anti-inflammatory properties of NSAIDs such as naproxen sodium.
Therefore, the investigators propose to initiate a double-blind, pilot study to evaluate the anti-inflammatory and analgesic effects of an OTC regimen of naproxen sodium versus acetaminophen in dental implant surgery patients. Notably, the vast majority of these patients are over the age of 45, a patient demographic that is rarely captured in postsurgical dental pain studies. Compared to dental impaction surgery patients, implant surgery patients possess more comorbidities such as hypertension, hyperlipidemia and hyperglycemia Thus, while dental impaction patients are typically on few if any drugs, polypharmacy is more of the norm in dental implant surgery patients. Performing a controlled study with OTC naproxen sodium in this population will provide the opportunity to confirm that its short-term use is generally safe and effective in these older, more medically complex patients. It will also confirm that naproxen sodium in the OTC dosage range is a good alternative to immediate-release opioid formulations, which are subject to misuse, abuse and diversion in this patient population.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Double blind, randomized, active-controlled, two arms|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Administration of naproxen or acetaminophen will be masked by over-encapsulation|
|Primary Purpose:||Basic Science|
|Official Title:||Demonstration of OTC Naproxen Sodium's (Aleve's) Anti-inflammatory Action in Dental Implant Surgery Patients|
|Actual Study Start Date :||February 7, 2021|
|Estimated Primary Completion Date :||February 6, 2022|
|Estimated Study Completion Date :||April 6, 2022|
Experimental: Naproxen sodium
Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.
Then 220 mg every 8 hours for the next two days.
Other Name: Aleve
50 mg by mouth every 6 hours as needed for pain
Other Name: Ultram
Active Comparator: Acetaminophen
Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
Other Name: Extra Strength Tylenol
50 mg by mouth every 6 hours as needed for pain
Other Name: Ultram
- Prostaglandin E2 concentrations employing liquid chromatography/mass spectrometry [ Time Frame: Up to 3 days ]Assessment of PGE2 in urine and gingival crevicular fluid
- Tumor necrosis factor concentrations employing ELISA [ Time Frame: Up to 3 days ]Assessment of TNF levels in plasma
- Interleukin 6 concentrations employing ELISA [ Time Frame: Up to 3 days ]Assessment of IL-6 levels in plasma
- Pain intensity scores on numeric pain intensity scale [ Time Frame: Up to 6 hours ]Pain intensity scores where 0 = no pain and 10 = worst possible pain
- Rescue analgesic use [ Time Frame: Up to 3 days ]Need for opioid rescue medication (tramadol) in addition to blinded study medication
- 24-hour area under the pain intensity curve (SPI24) [ Time Frame: 1 day ]Derived from 0-10 numeric pain intensity scale (0= no pain, 10=worst possible pain)
- COX-2 activity [ Time Frame: Up to 3 days ]COX-2 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine and gingival crevicular fluid.
- COX-1 activity [ Time Frame: Up to 3 days ]COX-1 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04694300
|Contact: Elliot V Hersh, DMD, MS, PhDemail@example.com|
|Contact: Katherine N Theken, PharmD, PhDfirstname.lastname@example.org|
|United States, Pennsylvania|
|University of Pennsylvania School of Dental Medicine||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104-6030|
|Contact: Elliot V Hersh, DMD, MS, PhD 215-898-9686 email@example.com|
|Contact: Stacey Secreto, EMT, CCRC 215-746-8871 firstname.lastname@example.org|
|Principal Investigator: Elliot V Hersh, DMD, MS, PhD|
|Sub-Investigator: Jonathan Korostoff, DMD, PhD|
|Sub-Investigator: Yu Cheng Chang, DMD|
|Sub-Investigator: Joseph Fiorellini, DMD, DScD|
|Sub-Investigator: Thomas Yoo, DMD|
|Principal Investigator: Katherine N Theken, PharmD, PhD|
|Sub-Investigator: Claire Mitchell, PhD|
|Principal Investigator:||Elliot V Hersh, DMD, MS, PhD||University of Pennsylvania|
|Principal Investigator:||Katherine N Theken, PharmD, PhD||University of Pennsylvania School of Dental Medicine and Medicine|